CV Therapeutics CVTX announced on Monday that it plans to sell 7.5 million shares in an offering. This will increase the firm's shares by roughly 15%, and we'll lower our fair value estimate by a similar magnitude once the offering is completed. We're a little surprised to see the firm issue equity ...
Dr. Fredric N. Eshelman Files Preliminary Written Consent Statement in Connection with Puma Biotechnology Inc.
Given recent trial results and CV Therapeutics' CVTX financial position, we are placing the company under review to re-evaluate our assumptions about its capital-raising opportunities and Ranexa's peak sales if it receives approval as a first-line therapy for chronic angina.
Gilead's John Martin has established leading market share and spectacular profitability for the innovative biotech firm.